The present disclosure relates generally to the fields of immunology and molecular biology. More specifically, provided herein are pharmaceutical combinations comprising (A) antibodies, or antigen-binding portions thereof, directed against LY75, and (B) a second anti-cancer entity； nucleic acids encoding antibody combinations； methods for preparing antibody combinations； and methods for the treatment of diseases, such as cancers mediated by LY75 expression or activity.
